IVIEW Therapeutics Secures Series A++ Funding for Ophthalmology Pipeline

IVIEW Therapeutics Secures Series A++ Funding for Ophthalmology Pipeline

IVIEW Therapeutics Inc., an ophthalmology biotech operating out of the US and China, has reportedly raised an undisclosed amount of funds via a Series A++ financing round. The round was led by Chongqing Changsheng Shenghe Investment Fund, with contributions from Hangzhou Jiurun Investment, ehroh, and existing investors Proxima Ventures Fund I L.P and Prox Ventures. The proceeds will be used to advance clinical studies and regulatory filings for its pipeline programs.

Pipeline Programs and Clinical Progress
IVIEW boasts IVW-1001, a Category chemical drug for dry eye that has completed all patient treatments in Phase I/II studies across 10 centers in the US. Top-line results are expected during the first quarter of 2025. The company is also developing IVIEW-1201, a broad-spectrum acute treatment for conjunctivitis, which is slated for Phase III clinical filing in the US this year. Additionally, IVIEW’s in-house developed glaucoma gene therapy is anticipated to kick-start its first-in-human study during Q1 2025, based on excellent preclinical safety and efficacy data.

Strategic Implications
The Series A++ financing round is a significant milestone for IVIEW Therapeutics, providing the necessary capital to accelerate the development of its innovative ophthalmology pipeline. By advancing clinical studies and regulatory filings, IVIEW aims to bring new and effective treatments to patients with various eye conditions, addressing significant unmet medical needs in the ophthalmology field. This funding will support the company’s growth and contribute to the broader goal of improving eye health and patient outcomes.-Fineline Info & Tech

Leave a Reply

Your email address will not be published. Required fields are marked *

Fineline Info & Tech